Ami Asset Management Corp decreased its stake in 3M Company (MMM) by 1.69% based on its latest 2019Q1 regulatory filing with the SEC. Ami Asset Management Corp sold 1,584 shares as the company’s stock declined 16.98% while stock markets rallied. The hedge fund held 92,162 shares of the medical and dental instruments company at the end of 2019Q1, valued at $19.15 million, down from 93,746 at the end of the previous reported quarter. Ami Asset Management Corp who had been investing in 3M Company for a number of months, seems to be less bullish one the $97.35B market cap company. The stock increased 0.36% or $0.6 during the last trading session, reaching $168.89. About 1.47 million shares traded. 3M Company (NYSE:MMM) has declined 15.38% since June 11, 2018 and is downtrending. It has underperformed by 19.81% the S&P500. Some Historical MMM News: 04/04/2018 – 3M CO – KRISTEN LUDGATE IS APPOINTED SENIOR VICE PRESIDENT, HUMAN RESOURCES, EFFECTIVE JULY 1, 2018; 05/03/2018 – 3M CO – MICHAEL F. ROMAN IS APPOINTED CHIEF EXECUTIVE OFFICER, EFFECTIVE JULY 1, 2018; 21/05/2018 – 3M Forms Sustainability and Product Stewardship Organization; Names Dr. Gayle Schueller Next Chief Sustainability Officer; 22/03/2018 – Global Adhesives and Sealants Market 2018: Industry Analysis & Outlook 2022 Featuring 3M, Henkel, Arkema and H.B. Fuller – ResearchAndMarkets.com; 09/03/2018 – FDA: 3M Company – Health Care Business- ACE (TM) BRAND, DELUXE ANKLE BRACE, 207736, UPC 0 51131 20387 7; 08/05/2018 – 3M Annual Meeting Highlights 2017 Achievements; 05/03/2018 – 3M Names New CEO, Thulin To Become Executive Chair — MarketWatch; 13/04/2018 – Canada 3M CDOR Yield at 1.93% by End-3Q vs 1.90% Prior (Survey); 22/03/2018 – SAMHALLSBYGGNADSBOLAGET l NORDEN AB SBBb.ST – BONDS HAVE A FLOATING RATE CORRESPONDING TO STIBOR 3M PLUS 6.25 PERCENT AND ARE DUE IN JUNE 2018; 07/03/2018 – GRAPHIC-GE value could slip to lowest among large U.S. industrials
Taylor Asset Management Inc decreased its stake in Celgene Corp (CELG) by 22.05% based on its latest 2019Q1 regulatory filing with the SEC. Taylor Asset Management Inc sold 55,300 shares as the company’s stock rose 5.82% with the market. The hedge fund held 195,500 shares of the major pharmaceuticals company at the end of 2019Q1, valued at $18.44M, down from 250,800 at the end of the previous reported quarter. Taylor Asset Management Inc who had been investing in Celgene Corp for a number of months, seems to be less bullish one the $67.71B market cap company. The stock increased 0.75% or $0.71 during the last trading session, reaching $96. About 2.78 million shares traded. Celgene Corporation (NASDAQ:CELG) has risen 11.31% since June 11, 2018 and is uptrending. It has outperformed by 6.88% the S&P500. Some Historical CELG News: 09/04/2018 – KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3 KEYNOTE-042 STUDY, SIGNIFICANTLY IMPROVING OS AS FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC PATIENTS EXPRESSING P…; 09/04/2018 – MERCK & CO INC – SAFETY PROFILE OF KEYTRUDA IN PHASE 3 TRIAL WAS CONSISTENT; 23/05/2018 – MERCK & CO – BASED ON AN INTERIM ANALYSIS TREATMENT WITH KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY RESULTED IN LONGER OS & PFS THAN CHEMOTHERAPY ALONE; 21/05/2018 – EVOTEC AG EVTG.DE – UNDER TERMS OF AGREEMENT, EVOTEC WILL RECEIVE AN UPFRONT PAYMENT OF $65 MLN; 06/04/2018 – INCYTE- SAFETY PROFILE OBSERVED IN ECHO-301/KEYNOTE-252 WAS CONSISTENT WITH THAT OBSERVED IN STUDIES OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA; 16/04/2018 – BRISTOL-MYERS SQUIBB CO – SAFETY PROFILE FOR OPDIVO AT TWO-YEAR FOLLOW-UP WAS CONSISTENT WITH PREVIOUS ANALYSES FROM STUDY; 22/04/2018 – DJ Celgene Corporation, Inst Holders, 1Q 2018 (CELG); 16/04/2018 – PFS RATE AFTER 1 YEAR 43 PCT FOR BRISTOL-MYERS’ OPDIVO PLUS YERVOY VS 13 PCT FOR CHEMOTHERAPY – DATA; 24/05/2018 – Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization And Plans To Execute A $2 Billion Accelerated Share Repurchase Program; 26/04/2018 – BRISTOL-MYERS SQUIBB CO – QTRLY OPDIVO WORLDWIDE REVENUE $1,511 MLN VS $1,127 MLN REPORTED LAST YEAR
Investors sentiment increased to 0.76 in 2019 Q1. Its up 0.12, from 0.64 in 2018Q4. It increased, as 108 investors sold CELG shares while 441 reduced holdings. 204 funds opened positions while 213 raised stakes. 482.72 million shares or 1.75% less from 491.33 million shares in 2018Q4 were reported. Massachusetts Svcs Co Ma owns 266,046 shares. Fiduciary Trust stated it has 0.07% of its portfolio in Celgene Corporation (NASDAQ:CELG). Ironwood Fincl Ltd Com reported 0% stake. Oppenheimer Asset Mgmt has 310 shares. Cap Investment Advsrs Limited Co has invested 0.01% in Celgene Corporation (NASDAQ:CELG). Bankshares Of The West owns 11,670 shares. Arrow Fincl Corp holds 0.32% or 14,744 shares in its portfolio. Bluemountain Capital Management Limited Liability Company owns 215,872 shares for 0.23% of their portfolio. Parnassus Invs Ca invested 0.33% in Celgene Corporation (NASDAQ:CELG). Ccm Inv Advisers Limited Liability Corporation invested in 0.05% or 3,050 shares. North Star Invest Management reported 4,310 shares. New York-based Kings Point Capital Mgmt has invested 0.01% in Celgene Corporation (NASDAQ:CELG). Psagot Inv House Ltd stated it has 0.05% of its portfolio in Celgene Corporation (NASDAQ:CELG). Gofen & Glossberg Limited Liability Com Il accumulated 212,716 shares or 0.71% of the stock. Gideon Capital Advsrs Inc reported 0.14% in Celgene Corporation (NASDAQ:CELG).
Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on July, 25. They expect $2.45 EPS, up 31.72% or $0.59 from last year’s $1.86 per share. CELG’s profit will be $1.73B for 9.80 P/E if the $2.45 EPS becomes a reality. After $2.28 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 7.46% EPS growth.
More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Streetinsider.com which released: “Celgene (CELG) Announces FDA and EMA Accept Applications for Ozanimod for Treatment of Relapsing Forms of MS – StreetInsider.com” on June 06, 2019, also Benzinga.com with their article: “Ideaya Biosciences IPO: What You Need To Know (NASDAQ:IDYA) – Benzinga” published on May 22, 2019, Nasdaq.com published: “Mallinckrodt (MNK) Down After Filing Suit Against HHS and CMS – Nasdaq” on May 22, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Bizjournals.com and their article: “Amid IPO rumors, this biotech unicorn lands ex-Bayer exec as fourth CEO in 22 months – San Francisco Business Times” published on June 10, 2019 as well as Nasdaq.com‘s news article titled: “Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay? – Nasdaq” with publication date: May 21, 2019.
Since February 7, 2019, it had 0 buys, and 1 insider sale for $2.05 million activity.
Investors sentiment increased to 0.98 in Q1 2019. Its up 0.18, from 0.8 in 2018Q4. It increased, as 55 investors sold MMM shares while 546 reduced holdings. 135 funds opened positions while 452 raised stakes. 375.82 million shares or 5.73% less from 398.67 million shares in 2018Q4 were reported. Van Hulzen Asset Llc has 0.76% invested in 3M Company (NYSE:MMM). James Inv Research owns 23 shares for 0% of their portfolio. M&T Commercial Bank Corp holds 0.5% or 456,777 shares in its portfolio. Violich Mngmt has invested 0.41% in 3M Company (NYSE:MMM). Fiduciary Fincl Of The Southwest Tx has 5,790 shares. 809,709 are held by Apg Asset Nv. Mckinley Capital Management Ltd Liability Corp Delaware holds 1,266 shares. Boston And Mngmt Inc invested in 24,336 shares or 2.11% of the stock. Hengehold Capital Ltd Liability Co invested in 1,517 shares. Lee Danner Bass Incorporated has invested 0.25% in 3M Company (NYSE:MMM). 41,961 were reported by Cape Cod Five Cents Bancshares. Moreover, Utd Financial Advisers Ltd Liability Company has 0.17% invested in 3M Company (NYSE:MMM). Commonwealth Comml Bank Of Aus holds 0.16% or 80,042 shares. Elm Limited Liability reported 0.52% in 3M Company (NYSE:MMM). Truepoint Incorporated reported 0.03% stake.
Analysts await 3M Company (NYSE:MMM) to report earnings on July, 23. They expect $2.04 earnings per share, down 21.24% or $0.55 from last year’s $2.59 per share. MMM’s profit will be $1.18B for 20.70 P/E if the $2.04 EPS becomes a reality. After $2.23 actual earnings per share reported by 3M Company for the previous quarter, Wall Street now forecasts -8.52% negative EPS growth.
Since January 30, 2019, it had 1 insider buy, and 10 sales for $17.27 million activity. 4,220 shares were sold by Bushman Julie L, worth $841,392 on Thursday, February 7. Keel Paul A had sold 9,410 shares worth $1.87M on Friday, February 8. Gangestad Nicholas C sold $942,450 worth of 3M Company (NYSE:MMM) on Thursday, February 7. Shares for $1.63M were sold by Vrohidis Ippocratis. 13,499 3M Company (NYSE:MMM) shares with value of $2.70M were sold by THULIN INGE G. The insider Vale Michael G. sold 8,906 shares worth $1.77 million.
Ami Asset Management Corp, which manages about $1.42 billion and $1.36 billion US Long portfolio, upped its stake in Asgn Incorporated by 34,256 shares to 180,457 shares, valued at $11.46M in 2019Q1, according to the filing. It also increased its holding in Mgp Ingredients Inc Com (NASDAQ:MGPI) by 35,234 shares in the quarter, for a total of 152,175 shares, and has risen its stake in Walgreens Boots Allian Com.
More notable recent 3M Company (NYSE:MMM) news were published by: Streetinsider.com which released: “TRC Lowers Price of Tender Offer for 3M Company (MMM) – StreetInsider.com” on May 22, 2019, also Seekingalpha.com with their article: “3M And The Growth Trap (Podcast) – Seeking Alpha” published on May 29, 2019, Seekingalpha.com published: “3M And The Growth Trap (Podcast Transcript) – Seeking Alpha” on May 31, 2019. More interesting news about 3M Company (NYSE:MMM) were released by: Investorplace.com and their article: “2 Dividend Stocks to Buy That Are Better Than 3M Stock – Investorplace.com” published on June 07, 2019 as well as Seekingalpha.com‘s news article titled: “3M Co.: Be Greedy When Others Are Fearful – Seeking Alpha” with publication date: May 12, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.